ArticleBlood cell therapy2026
Fecal Calprotectin as a biomarker for early diagnosis and prediction of steroid response in Acute Gastrointestinal Graft versus Host Disease.
Article in Blood cell therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute gastrointestinal graft-versus-host disease (GI-GVHD) is a complication of allogeneic hematopoietic stem cell transplantation (HSCT) that requires early diagnosis. Fecal calprotectin (FC) is a biomarker of intestinal inflammation. We studied the role of FC in differentiating GI-GVHD from other diarrhea. Methods: We prospectively studied allogeneic HSCT recipients between 2017 and 2020. FC levels were measured pre-transplant, on post-transplant day 14, on day 1 of diarrhea, and post-steroid treatment (day 3-7 of steroid treatment). Results: We studied 116 patients with median age 14.5 (5-29) years; 84 were male (72.4%). Fifty-seven patients (49.1%) developed diarrhea post-HSCT, 34 (59.7%) patients had GI-GVHD, and 23 patients (40.3%) developed other diarrheal illnesses. FC level on day1 of diarrhea among GI-GVHD patients (n=33) was higher (63 μg/g [Q1-Q3:25.6-358.5]) compared to other diarrhea (27.5 μg/g [21.1-60.4], Conclusion: A higher FC value on day 1 of diarrhea aids in the diagnosis of acute GI-GVHD and predicts poor response to treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.